16 documents found, page 1 of 2
Molecular Profiling of Axial Spondyloarthritis Patients Reveals an Association ...
Sobral, Daniel; Fernandes, Ana Filipa; Bernardes, Miguel; Pinto, Patrícia; Santos, Helena; Gomes, JL; Tavares-Costa, José; Silva, José A.P.Funding Information: D.S. was funded by a fellowship from Fundação para a Ciência e Tecnologia (PTDC/MED535 ONC/28660/2017). This study was funded by Abbvie but the funder had no influence in study design, data analysis, or writing of the submitted document. Publisher Copyright: © 2024 by the authors.; This study aims at identifying molecular biomarkers differentiating responders and non-responders to treatment...
Impact of Risk Factors on COVID-19 Outcomes in Unvaccinated People With Rheumat...
Yazdany, Jinoos; Ware, Anna; Wallace, Zachary S.; Bhana, Suleman; Grainger, Rebecca; Hachulla, Eric; Richez, Christophe; Cacoub, PatriceFunding Information: Supported by the American College of Rheumatology and European Alliance of Associations for Rheumatology. Dr. Duarte‐García's work was supported by the Rheumatology Research Foundation Scientist Development Award and the Centers for Disease Control and Prevention. Dr. Machado's was supported by the NIHR University College London Hospitals Biomedical Research Centre. Publisher Copyright: © 2...
Measuring quality of life of patients with axial spondyloarthritis for economic...
Hernandez Alava, Monica; Wailoo, Allan; Chrysanthou, Georgios; Barcelos, Filipe; van Gaalen, Floris A.; Santos, Helena; Fagerli, Karen MindePublisher Copyright: © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.; OBJECTIVES: To estimate the relationship between EQ5D (three levels, UK version) and the Ankylosing Spondylitis Disease Activity Score (ASDAS) for use in the economic evaluation of health technologies for people with axial spondyloarthritis (axSpA). ...
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axia...
Marona, José; Sepriano, Alexandre; Rodrigues Manica, Santiago; M. Pimentel-Santos, F.; Mourão, Ana Filipa; Gouveia, Nélia; Branco, Jaime; Santos, HelenaThis work was supported by a Research Grant from the InvestigatorInitiated Studies program of Merck Sharp & Dohme (Grant No. 56078). The sponsor did not interfere with the study question, analysis or interpretation of results. AS is supported by a doctoral grant from Fundação para a Ciência e Tecnologia (Foundation for Science and Technology) (SFRH/BD/108246/2015).; OBJECTIVES: To compare definitions of high di...
Effectiveness of switching between TNF inhibitors in patients with axial spondy...
Rodrigues Manica, Santiago; Sepriano, Alexandre; M. Pimentel-Santos, F.; Gouveia, Nélia; Barcelos, Anabela; Branco, Jaime; Bernardes, Miguel57763]. AS is supported by a doctoral grant from “Fundação para a Ciência e Tecnologia” (SFRH/BD/108246/2015).; Background: To investigate whether the reason to discontinue the first TNF inhibitor (TNFi) affects the response to the second TNFi in axial spondyloarthritis (axSpA). Methods: Patients with axSpA from the Rheumatic Diseases Portuguese Register (ReumaPt), who discontinued their first TNFi and started ...
Rheuma SPACE - Standard Practice Aiming Clinical Excellence
Macieira, Carla; Cunha-Miranda, L.; Nero, P.; Laires, P.; Bogas, M.; Farinha, S.; Freitas, I; Lucas, P.; Sousa, J.; Narciso, L.; Mateus, E.
Predictors and causes of first-line biologic agent discontinuation in rheumatoi...
Gomes, JL; Sepriano, Alexandre; Eusébio, Mónica; Silvério Serra, Sofia; Fonseca, João Eurico; Saavedra, Maira João; Cunha-Miranda, Luís; Silva, CândidaOBJECTIVES: To assess the discontinuation of first-line biological treatment and to evaluate the reasons and predictors thereof in patients with rheumatoid arthritis (RA) from daily clinical practice. METHODS: RA patients registered in the Rheumatic Diseases Portuguese Register (Reuma.pt) starting treatment with biologic DMARDs (bDMARDs) were included in this prospective observational study. The main outcome wa...
Real-life effectiveness of Golimumab in biologic-naive patients with rheumatoid...
Mourao, A. F.; Ribeiro, Célia; Borges, Joana; Goncalves, M. J.; Bernardes, Miguel; Fernandes, Susana; Dezerto, Raquel; Laires, P. A.; Machado, Patrícia
Portuguese recommendations for the use of methotrexate in rheumatic diseases - ...
Duarte, Ana Catarina; Santos-Faria, Daniela; Gonçalves, Maria João; Sepriano, Alexandre; Mourão, Ana Filipa; Duarte, Cátia; Neves, Joana SousaBACKGROUND: Methotrexate (MTX) is the first-line drug in the treatment of rheumatoid arthritis (RA) and the most commonly prescribed disease modifying anti-rheumatic drug. Moreover, it is also used as an adjuvant drug in patients under biologic therapies, enhancing the efficacy of biologic agents. OBJECTIVES: To review the literature and update the Portuguese recommendations for the use of MTX in rheumatic dise...
Comparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthr...
Romão, Vasco C.; Santos, Maria José; Polido-Pereira, Joaquim; Duarte, Cátia; Nero, Patrícia; Miguel, Cláudia; Costa, José António; Bernardes, MiguelObjectives. To compare the effectiveness of TNF inhibitors (TNFi) and tocilizumab in rheumatoid arthritis (RA) treatment, according to different response criteria. Methods. We included RA patients registered in the Rheumatic Diseases Portuguese Register treated with TNFi or tocilizumab for at least 6 months, between January 2008 and July 2013. We assessed remission/low disease activity (LDA) at 6 months accordi...